Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of immunotherapy plus extensive radiotherapy in stage IV non-small cell lung cancer
2021-003266-13Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab and cemiplimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Acute toxicity and Subacute toxicity. Started Jul 2021; status: active.
02
Drugs
pembrolizumabcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-003266-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003266-13.